



Drugs for Neglected Diseases

Partnership in Research & Development



“today, a growing injustice confronts us. More than 90% of all death and suffering from infectious diseases occurs in the developing world.

Some of the reasons that people die from diseases like HIV/AIDS, TB, sleeping sickness, and other tropical diseases is that life saving essential medicines are either too expensive, are not available because they are not seen as financially viable, or because there is virtually no new research and development for tropical diseases.

“This market failure is our next challenge”


Noble Lecture delivered by Dr. James Orbinski after MSF was awarded the Nobel Peace Prize in 1999



Core Diseases



Human African Trypanosomiasis (Sleeping Sickness): Endemic in 36 African Countries



Leishmaniasis: occurs in 98 countries with 350 million people living at risk.



Chagas Disease: Endemic in 21 countries in South America



Malaria: 219 million new cases 660,000 deaths* (World Malaria Report 2012)



Pediatric HIV: 3.4 million children under 15 living with HIV in 2011



Helminth Infection (River Blindness): 120 million infected, 40 million symptomatic

Neglected Disease Control Challenges

- Populations live in poor, remote, sometimes politically unstable areas
- Health system capacity
- Inappropriate or nonexistent diagnostic tools
- No effective vaccines
- Existing drugs toxic, difficult to administer, long course, expensive



DNDi Objectives

- Primary Objective:
 - **To deliver 11-13 new treatments by 2018** for sleeping sickness, Chagas, leishmaniasis, & malaria & a robust pipeline for future needs
- Secondary Objectives:
 - **Use and strengthen existing capacity** in endemic countries
 - **Raise awareness** about the need to develop new drugs for neglected diseases
 - **and advocate for increased public responsibility**



Six Treatments Delivered so far.....

Examples:

2007

ASAQ (Malaria)
Fixed-Dose
Artesunate/
Amodiaquine



Partnership
with sanofi-
aventis

(France)

2008

ASMQ (Malaria)
Fixed-Dose
Artesunate/
Mefloquine



Farmanguinhos

(Brazil)

Cipla

(India)

2009

NECT
Sleeping Sickness




National Control
Programs

MSF

WHO

- Easy to Use
- Affordable
- Field-Adapted
- Non-Patented

Multi Drug Resistant-TB



Our Patients & Medical Staff Call For:

- For better treatment regimens: the TB research community, including research institutes and drug companies, must urgently deliver effective, more tolerable, shorter and *affordable* DR-TB drug regimens.
- For more financial support to increase DR-TB treatment, and a commitment to support research into developing not only effective and safe new drugs, but also easy-to-use, accurate and affordable diagnostics

Thank You

**Best
science
for the
most
neglected**